Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046050 in adults with advanced CEACAM5-expressing solid tumors
NL-OMON60691Phase 1Recruiting
- Sponsor
- Seagen Inc.
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF-08046050 in Pulmonary squamous cell carcinoma, gastroesophageal junction adenocarcinoma, pancreatic cancer (PC) and 4 more, sponsored by Seagen Inc. Started Oct 2024; status: recruiting.
02
Drugs
PF-08046050
03
Conditions
Pulmonary squamous cell carcinomagastroesophageal junction adenocarcinomapancreatic cancer (PC)small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60691.